Medical Editor: John P. Cunha, DO, FACOEP
What Is Cefobid?
Cefobid (sterile cefoperazone) is a cephalosporin antibiotic used to treat infections caused by bacteria.
What Are Side Effects of Cefobid?
Common side effects of Cefobid include:
- hypersensitivity skin reactions including rash, injection site reactions (pain, swelling, or redness), or
- reversible low white blood cell count (neutropenia).
Dosage for Cefobid
Cefobid is administered by intravenous (IV) or intramuscular injection, as directed by your doctor.
What Drugs, Substances, or Supplements Interact with Cefobid?
Cefobid During Pregnancy and Breastfeeding
Consult your doctor before taking Cefobid if you are pregnant or breastfeeding.
Our Cefobid (sterile cefoperazone) Side Effects Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Clinical Trials Experience
In clinical studies the following adverse effects were observed and were considered to be related to CEFOBID therapy or of uncertain etiology:
As with all cephalosporins, hypersensitivity manifested by skin reactions (1 patient in 45), drug fever (1 in 260), or a change in Coombs’ test (1 in 60) has been reported. These reactions are more likely to occur in patients with a history of allergies, particularly to penicillin.
As with other beta-lactam antibacterial drugs, reversible neutropenia may occur with prolonged administration. Slight decreases in neutrophil count (1 patient in 50) have been reported. Decreased hemoglobins (1 in 20) or hematocrits (1 in 20) have been reported, which is consistent with published literature on other cephalosporins. Transient eosinophilia has occurred in 1 patient in 10.
Of 1285 patients treated with cefoperazone in clinical trials, one patient with a history of liver disease developed significantly elevated liver function enzymes during CEFOBID therapy. Clinical signs and symptoms of nonspecific hepatitis accompanied these increases. After CEFOBID therapy was discontinued, the patient’s enzymes returned to pre-treatment levels and the symptomatology resolved. As with other antibacterial drugs that achieve high bile levels, mild transient elevations of liver function enzymes have been observed in 5–10% of the patients receiving CEFOBID therapy. The relevance of these findings, which were not accompanied by overt signs or symptoms of hepatic dysfunction, has not been established.
Diarrhea or loose stools has been reported in 1 in 30 patients. Most of these experiences have been mild or moderate in severity and self-limiting in nature. In all cases, these symptoms responded to symptomatic therapy or ceased when cefoperazone therapy was stopped. Nausea and vomiting have been reported rarely.
Renal Function Tests
Transient elevations of the BUN (1 in 16) and serum creatinine (1 in 48) have been noted.
CEFOBID is well tolerated following intramuscular administration. Occasionally, transient pain (1 in 140) may follow administration by this route. When CEFOBID is administered by intravenous infusion some patients may develop phlebitis (1 in 120) at the infusion site.
The following adverse reactions have been identified during post-approval use of CEFOBID. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Hepatobiliary Disorders: Jaundice, hepatic dysfunction
Read the entire FDA prescribing information for Cefobid (Sterile Cefoperazone)
© Cefobid Patient Information is supplied by Cerner Multum, Inc. and Cefobid Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.